The effects of rosiglitazone and metformin on menstrual cyclicityand hirsutism in polycystic ovary syndrome

References

• Frank S. Polycystic ovary syndrome. N Engl J Med 1995; 333: 853–861
   PubMed Web of Science ®Google Scholar
• Nestler J E, Jakubowicz D J, Evans W S, Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 1998; 338: 1876–1880
   PubMed Web of Science ®Google Scholar
• Dunaif A, Segal K, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989; 38: 1165–1174
   PubMed Web of Science ®Google Scholar
• Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997; 18: 774–800
   PubMed Web of Science ®Google Scholar
• Bailey C J, Turner R C. Metformin. N Engl J Med 1996; 334: 574–579
   PubMed Web of Science ®Google Scholar
• Baillargeon J P, Jakubowicz D J, Iuorno M J, Jakubowicz S, Nestler J E. Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertil Steril 2004; 82: 893–902
   PubMed Web of Science ®Google Scholar
• Hoeger K M, Kochman L, Wixom N, Craig K, Miller R K, Guzick D S. A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertil Steril 2004; 82: 421–429
   PubMed Web of Science ®Google Scholar
• La Marca A, Egbe T O, Morgante G, Paglia T, Cianci A, De Leo V, Ciani A. Metformin treatment reduces ovarian cytochrome P-450c17 response to human chorionic gonadotropin in women with insulin resistance-related polycystic ovary syndrome. Hum Reprod 2000; 15: 21–23
   PubMed Web of Science ®Google Scholar
• Moghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo M, Zanolin E, Muggeo M. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 2000; 85: 139–146
   PubMed Web of Science ®Google Scholar
• Morin-Papunen L C, Koivunen R M, Ruokonene A, Martikainen H K. Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. Fertil Steril 1998; 69: 691–696
   PubMed Web of Science ®Google Scholar
• Unluhizarci K, Kelestimur F, Bayram F, Sahin Y, Tutus A. The effects of metformin on insulin resistance and ovarian steroidogenesis in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 1999; 51: 231–236
   PubMed Web of Science ®Google Scholar
• Kolodziecjzyk B, Dubela A J, Spaczynski R Z, Pawelczyk L. Metformin therapy decreases hyperandrogenizm and hyperinsulinemia in women with polycystic ovary syndrome. Fertil Steril 2000; 73: 1149–1154
   Google Scholar
• Vandermolen D T, Patts V S, Evans W S. Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertil Steril 2001; 75: 310–315
   PubMed Web of Science ®Google Scholar
• Fleming R, Hopkinson Z E, Wallace A M, Greer I A, Satar N. Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial. J Clin Endocrinol Metab 2002; 87: 569–574
   PubMed Web of Science ®Google Scholar
• Kocak M, Caliskan E, Simsir C, Haberal A. Metformin therapy improves ovulatory rates, cervical scores, and pregnancy rates in clomiphene citrate-resistant women with polycystic ovary syndrome. Fertil Steril 2002; 77: 101–106
   PubMed Web of Science ®Google Scholar
• Jakubowicz D J, Iuorno M J, Jakubowicz S, Roberts K A, Nestler J E. Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J Clin Endocrinol Metab 2002; 87: 524–529
   PubMed Web of Science ®Google Scholar
• Goldstein B J. Current views on the mechanisms of action of thiazolidinedione insulin sensitizers. Diabetes Technol Ther 1999; 1: 267–275
   PubMedGoogle Scholar
• Ghazeeri G, Kutteh W H, Bryer-Ash M, Haas D, Ke E W. Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome. Fertil Steril 2003; 79: 562–566
   PubMed Web of Science ®Google Scholar
• Belli S, Graffigma M, Oneto A, Otero P, Schurman L, Levalle O. Effect of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with polycystic ovary syndrome. Fertil Steril 2004; 81: 624–629
   PubMed Web of Science ®Google Scholar
• Shobokshi A, Shaarawy M. Correction of insulin resistance and hyperandrogenism in polycystic ovary syndrome by combined rosiglitazone and clomiphene citrate therapy. J Soc Gynecol Investig 2003; 10: 99–104
   PubMed Web of Science ®Google Scholar
• Sepilian V, Nagamani M. Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance. J Clin Endocrinol Metab 2005; 90: 60–65
   PubMed Web of Science ®Google Scholar
• Cataldo N, Abassi F, McLaughlin T, Lamendola C, Reaven G. Improvement in insulin sensitivity followed by ovulation and pregnancy in a woman with polycystic ovary syndrome who was treated with rosiglitazone. Fertil Steril 2001; 75: 1057–1059
   Google Scholar
• Pasquali R, Gambineri A, Biscotti D, Vicennati V, Gagliardi L, Colitta D, Fiorini S, Cognigni G E, Filicori M, Morselli-Labate A M. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J Clin Endocrinol Metab 2000; 85: 2767–2574
   PubMed Web of Science ®Google Scholar
• Gania M A, Khurana M L, Eunice M, Gulati M, Dwivedi S N, Amini A C. Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: an open-labeled study. J Clin Endocrinol Metab 2004; 89: 2756–2762
   Google Scholar
• Morin-Papunen L C, Vauhkonen I, Koivunen R M, Ruokonen A, Martikainen H K, Tapanainen J S. Endocrine and metabolic effects of metformin versus ethinyl estradiol–cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab 2000; 85: 3161–3168
   PubMed Web of Science ®Google Scholar
• Kriplani A, Agarwal N. Effects of metformin on clinical and biochemical parameters in polycystic ovary syndrome. Reprod Med 2004; 49: 361–367
   PubMed Web of Science ®Google Scholar
• Harborne L, Fleming R, Lyall H, Satar N, Norman J. Metformin and antiandrogen treatment in the treatment of polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88: 4216–4223
   Google Scholar
• Kazerooni T, Dehghan-Kooshkghazi M. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome. Gynecol Endocrinol 2003; 17: 51–56
   PubMed Web of Science ®Google Scholar
• Azziz R, Ehrmann D, Legro R S, Whitcomb R W, Hanley R, Fereshetian A G. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab 2001; 86: 1626–1632
   PubMed Web of Science ®Google Scholar
• The Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 81: 19–25
   Google Scholar
• Ferriman D, Gallwey J D. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961; 21: 1440–1447
   PubMed Web of Science ®Google Scholar
• Genuth S, Alberti K G, Bennett P, Buse J, Defronzo R, Kahn R, Kitzmiller J, Knowler W C, Lebovitz H, Lernmark A, et al. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26: 3160–3167
   PubMed Web of Science ®Google Scholar
• Franks S, Gilling-Smith C, Watson H, Willis D. Insulin action in the normal and polycystic ovary. Endocrinol Metab Clin North Am 1999; 28: 361–378
   PubMed Web of Science ®Google Scholar
• Gilling-Smith C, Willis D S, Beard R W, Franks S. Hypersecretion of androstenedione by isolated thecal cells from polycystic ovaries. J Clin Endocrinol Metab 1994; 79: 1158–1165
   PubMed Web of Science ®Google Scholar
• Cara J F, Fan J, Azzarello J, Rosenfield R L. Insulin-like growth factor I enhances luteinizing hormone binding to rat ovarian theca-interstitial cells. J Clin Invest 1990; 86: 560–565
   Google Scholar
• Nestler J E, Powers L P, Matt D W, Steingold K A, Plymate S R, Rittmaster R S. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 1991; 72: 83–89
   PubMed Web of Science ®Google Scholar
• Kelestimur F, Sahin Y. Alternate pathway 17,20-lyase enzyme activity in the adrenals is enhanced in patients with polycystic ovary syndrome. Fertil Steril 1999; 71: 1075–1078
   Google Scholar
• Legro R S, Finegood D, Dunaif A. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1998; 83: 2694–2698
   PubMed Web of Science ®Google Scholar
• Matthews D R, Hosker J P, Rudenski A S, Naylor B A, Treacher D F, Turner R C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412–419
   PubMed Web of Science ®Google Scholar
• Bulgan Kilicdag E, Bagis T, Zeyneloglu H B, Tarim E, Aslan E, Haydardedeoglu B, Erkanli S. Homocysteine levels in women with polycystic ovary syndrome treated with metformin versus rosiglitazone: a randomized study. Hum Reprod 2004; 23: 1–6
   Google Scholar
• Azziz R, Ehrman D, Legro R S, Fereshetian A G, O'Keefe M, Ghazzi M N. Troglitazone decreases adrenal androgen levels in woman with polycystic ovary syndrome. Fertil Steril 2003; 79: 932–937
   PubMed Web of Science ®Google Scholar
• Arlt W, Auchus R J, Miller W. Thiazolidinediones but not metformin directly inhibit the steroidogenic enzymes P450c17 and 3β-hydroxysteroid dehydrogenase. J Biol Chem 2001; 276: 16767–16771
   PubMed Web of Science ®Google Scholar
• Duplay D. Avandia Product Information (White pages). Physicians Desk References. Thomson PDR, New Jersey, 401–3534
   Google Scholar
• Coetzee E J, Jackson W PU. Metformin in management of pregnant insulin-independent diabetics. Diabetologia 1979; 16: 241–245
   PubMed Web of Science ®Google Scholar